Can Sodium‐Glucose Co‐Transporter‐2 Inhibitors Improve Sleep Quality, Anxiety, and Quality of Life in Patients With Heart Failure?
Yazarlar (6)
Dr. Öğr. Üyesi İlke Erbay Zonguldak Bülent Ecevit Üniversitesi, Türkiye
Dr. Öğr. Üyesi Naile Eriş Güdül Zonguldak Bülent Ecevit Üniversitesi, Türkiye
Ahmet Furkan Süner
Dr. Öğr. Üyesi Pelin Aladağ Türkiye
Umıt Karacar
Prof. Dr. Ahmet AVCI Kastamonu Üniversitesi, Türkiye
| Makale Türü |
Özgün Makale
(SSCI, AHCI, SCI, SCI-Exp dergilerinde yayınlanan tam makale)
|
||
| Dergi Adı | Clinical Cardiology (Q2) | ||
| Dergi ISSN | 0160-9289 Wos Dergi Scopus Dergi | ||
| Dergi Tarandığı Indeksler | SCI-Expanded | ||
| Makale Dili | İngilizce | Basım Tarihi | 08-2025 |
| Cilt / Sayı / Sayfa | 48 / 8 / – | DOI | 10.1002/clc.70190 |
| Makale Linki | https://doi.org/10.1002/clc.70190 | ||
| Özet |
| Background Sodium‐glucose co‐transporter‐2 (SGLT2) inhibitors improve cardiovascular outcomes in heart failure (HF), but their effect on sleep quality (SQ) and patient‐centered outcomes remains unclear. Objective This study aims to evaluate the impact of SGLT2 inhibitor use on SQ, anxiety, and quality of life in patients with HF. Methods This longitudinal observational study included 95 HF patients grouped by SGLT2 inhibitor use. A total of 79 patients (SGLT2 inhibitor group: 33; non‐SGLT2 inhibitor group: 46) completed a 6‐month follow‐up. Sleep quality was assessed using the Pittsburgh Sleep Quality Index (PSQI), anxiety with the Beck Anxiety Inventory (BAI), and quality of life with the Short Form‐36 (SF‐36). Subgroup analyses were conducted based on left ventricular ejection fraction (LVEF), and logistic regression was used to identify predictors of PSQI improvement. Results At baseline, PSQI … |
| Anahtar Kelimeler |
BM Sürdürülebilir Kalkınma Amaçları
| Atıf Sayıları | |
| Google Scholar | 4 |